# PDUFA dates March 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-03

> 351 FDA catalysts are dated in March 2025, including 7 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in March 2025?

PDUFA dates in March 2025: ARS Pharmaceuticals, Inc. (SPRY) on March 6, 2025; Scienture Holdings, Inc. (SCNX) on March 17, 2025; AMVUTTRA® (vutrisiran, ALNY) on March 23, 2025; ALNYLAM PHARMACEUTICALS, INC. (ALNY) on March 23, 2025; TLX007 (TLX) on March 24, 2025; CARDAMYST (etripamil, MIST) on March 27, 2025; and 1 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-03)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-005014, https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559dex991.htm (retrieved 2026-11-12). Last confirmed 2025-01-13. Cite: https://sec-api.dev/fda-calendar/2025-03#answer

## PDUFA dates in March 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| March 6, 2025 | ARS Pharmaceuticals, Inc. | SPRY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559dex991.htm) |
| March 17, 2025 | Scienture Holdings, Inc. | SCNX |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1382574/000149315226013475/form10-k.htm) |
| March 23, 2025 | ALNYLAM PHARMACEUTICALS, INC. | ALNY | AMVUTTRA® (vutrisiran) | with ATTR amyloidosis with cardiomyopathy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm) |
| March 23, 2025 | ALNYLAM PHARMACEUTICALS, INC. | ALNY |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm) |
| March 24, 2025 | Telix Pharmaceuticals Ltd | TLX | TLX007 |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm) |
| March 27, 2025 | Milestone Pharmaceuticals Inc. | MIST | CARDAMYST (etripamil) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm) |
| March 28, 2025 | Mirum Pharmaceuticals, Inc. | MIRM | CTEXLI® (chenodiol) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113xexx991.htm) |

## All catalysts in March 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 3, 2025 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/nmra-ex99_1.htm)) |
| March 3, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_ex99-1.htm)) |
| March 3, 2025 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera" | completed, positive | "The topline results of this study were announced on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera"." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000164/form6k_120825.htm)) |
| March 3, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025002002/avbp-20250303xex99d1.htm)) |
| March 3, 2025 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Reports Fourth Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647325000051/a4q2024exhibit991.htm)) |
| March 3, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm)) |
| March 3, 2025 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/annx-ex99_1.htm)) |
| March 3, 2025 | [TG THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tgtx/catalysts) | TGTX |  | completed | "TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/ex_782107.htm)) |
| March 3, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-ex99_1.htm)) |
| March 3, 2025 | [Corcept NDA/BLA submission](https://sec-api.dev/pdufa/corcept) | CORT | with endogenous hypercortisolism | completed | "On March 3, 2025, Corcept Therapeutics Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration filed the Company's New Drug Application submission for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293d8k.htm)) |
| March 3, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/ibrx-202533x8kexhibit991.htm)) |
| March 3, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Cassava Sciences Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/exh_991.htm)) |
| March 3, 2025 | [Tivoxavir marboxil topline data readout](https://sec-api.dev/pdufa/tivoxavir-marboxil) | TRAW | respiratory viral diseases, today | completed, positive | "Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline results from ferrets infected with H5N1 bird flu, an accepted animal model for human influenza, when treated with tivoxavir marboxil as a single dose." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925019446/tm258064d1_ex99-1.htm)) |
| March 3, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/a2024q4bhvnltdearningsprex.htm)) |
| March 3, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs2024-12x31ex99earningsr.htm)) |
| March 3, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/ef20044777_ex99-1.htm)) |
| March 3, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today reported financial results for the fourth quarter and year ended December 31, 2024 and provided recent business highlights, including updates to the registrational program for AXPAXLI™ (axitinib intravitreal hydrogel) in wet age-related macular degeneration (wet AMD) designed to accelerate a potential path to NDA submission and increased label flexibility." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_ex99-1.htm)) |
| March 3, 2025 | [Tevimbra (tislelizumab-jsgr) FDA approval](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761380 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20250303, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (islelizumab-jsgr)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761380%22)) |
| March 4, 2025 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/tm258273d1_ex99-1.htm)) |
| March 4, 2025 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "MINNEAPOLIS - March 4, 2025 - Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth quarter and fiscal year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000155837025002104/vreof-20250304xex99d1.htm)) |
| March 4, 2025 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | completed | "On March 4, 2025, Capricor Therapeutics, Inc. (the "Company" or "Capricor") issued a press release announcing announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its Biologics License Application ("BLA") seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000155837025002097/capr-20250304x8k.htm)) |
| March 4, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-ex99_1.htm)) |
| March 4, 2025 | [Acetadote® (acetylcysteine) label expansion decision](https://sec-api.dev/pdufa/acetylcysteine) | CPIX |  | completed, approved | "Cumberland announced the FDA approval of a supplemental New Drug Application for Acetadote, Cumberland's IV treatment for preventing or lessening liver injury after ingestion of potentially toxic quantities of acetaminophen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/a2024q4ex991earningsrelease.htm)) |
| March 4, 2025 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/a2024earningspressrelease.htm)) |
| March 4, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Record Fourth Quarter and Full Year 2024 Financial Results; Reaffirms 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/q42024eolsex991.htm)) |
| March 4, 2025 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525044876/d785711dex991.htm)) |
| March 4, 2025 | [CUMBERLAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/cpix/catalysts) | CPIX |  | completed | "Cumberland will report its 2024 financial results via a conference call today, March 4, 2025, at 4:30 p.m. Eastern Time." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1087294/000162828025009967/a2024q4ex991earningsrelease.htm)) |
| March 4, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Calif., March 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and full year ended December 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/tm258144d1_ex99-1.htm)) |
| March 4, 2025 | [TEVIMBRA® (tislelizumab) FDA approval](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On March 4, 2025, we announced the U.S. Food and Drug Administration has approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000075/bgne-20250331.htm)) |
| March 4, 2025 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Reports 2024 Fiscal Year Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/ea023288101ex99-1_adial.htm)) |
| March 4, 2025 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/pasg-20250304xex99d1.htm)) |
| March 5, 2025 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "CAMBRIDGE, Mass., March 5, 2025 - Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/editasmedicinepressrelease.htm)) |
| March 5, 2025 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/tcrx-ex99_1.htm)) |
| March 5, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/fate-ex99_1.htm)) |
| March 5, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "MALVERN, PA, March 5, 2025 (GLOBE NEWSWIRE) - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter and full year 2024 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305xex991.htm)) |
| March 5, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-q424xex991earningsrel.htm)) |
| March 5, 2025 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000012/ex991q42024_earningsxrelea.htm)) |
| March 5, 2025 | [ARS Pharmaceuticals, Inc. label expansion decision](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "U.S. Pediatric Approval: On March 5, 2025, the U.S. FDA approved ARS Pharma's sNDA for neffy 1 mg as an emergency treatment for Type I allergic reactions, including anaphylaxis, in children aged four and older and weighing 15 kilograms to < 30 kilograms (33 to <66 lb.). neffy 1 mg is expected to be available in pharmacies starting in May 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-ex99_1.htm)) |
| March 5, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025020366/ea023264101ex99-1_protara.htm)) |
| March 5, 2025 | [ARS Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed, approved | "On March 5, 2025, ARS Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") approved neffy 1 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including anaphylaxis, in children who are aged four years and older and weigh ≥15 kilograms to <30 kilograms (≥33lbs. to <66 lbs.)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1671858/000119312525047351/d831088d8k.htm)) |
| March 6, 2025 | [ARS Pharmaceuticals, Inc. PDUFA date](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | scheduled | "Drug User Fee Act (PDUFA) target action date of March 6, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559dex991.htm)) |
| March 6, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737dex991.htm)) |
| March 6, 2025 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, March 6, 2025 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282225000008/pressreleaseearningsq403-0.htm)) |
| March 6, 2025 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_ex99-1.htm)) |
| March 6, 2025 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/alxo-ex99_1.htm)) |
| March 6, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2024 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/ex_778773.htm)) |
| March 6, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; March 6, 2025 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/exh991q42024earningsrelease.htm)) |
| March 6, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025002396/nxtc-20250306xex99d1.htm)) |
| March 6, 2025 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/d925111dex991.htm)) |
| March 6, 2025 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/acet-ex99_1.htm)) |
| March 6, 2025 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces 2024 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/ctmx-ex99_1.htm)) |
| March 6, 2025 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154125000014/bdtx-exhibit991_q42024.htm)) |
| March 6, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/vyne-20250306q42024exx991.htm)) |
| March 6, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525000275/e664243_ex99-1.htm)) |
| March 6, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/d940367dex991.htm)) |
| March 6, 2025 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/revb-ex99_1.htm)) |
| March 7, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm)) |
| March 7, 2025 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| March 7, 2025 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| March 7, 2025 | [Mekinist (trametinib; trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA217513 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217513%22)) |
| March 9, 2025 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000155837025002859/mgtx-20250309xex99d2.htm)) |
| March 10, 2025 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184325001352/exh_991.htm)) |
| March 10, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "On March 10, 2025, the Company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000162828025011459/mlys-20250310.htm)) |
| March 10, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm)) |
| March 10, 2025 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/lctx-ex99_1.htm)) |
| March 10, 2025 | [BEAM-302 interim data readout](https://sec-api.dev/pdufa/beam-302) | BEAM |  | completed, positive | "On March 10, 2025, Beam Therapeutics Inc. (the "Company") announced positive initial safety and efficacy data from its ongoing Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency ("AATD")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1745999/000119312525050334/d922493d8k.htm)) |
| March 10, 2025 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000095017025036306/okur-ex99_1.htm)) |
| March 10, 2025 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000095017025036264/engn-ex99_1.htm)) |
| March 10, 2025 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000095017025036296/tnya-ex99_1.htm)) |
| March 10, 2025 | [Ovid Therapeutics Inc. earnings report](https://sec-api.dev/companies/ovid/catalysts) | OVID |  | completed | "Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid2024q4exhibit991.htm)) |
| March 10, 2025 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/prld-ex99_1.htm)) |
| March 10, 2025 | [Trevi Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/trvi/catalysts) | TRVI | with RCC | completed, positive | "On March 10, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the "Company"), announced positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with refractory chronic cough ("RCC") (N=66)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1563880/000095017025036503/trvi-20250310.htm)) |
| March 10, 2025 | [FENNEC PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/fenc/catalysts) | FENC |  | completed | "FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310xex99d1.htm)) |
| March 10, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310xex99d1.htm)) |
| March 10, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/crbu-20250310xexx991.htm)) |
| March 10, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/dsgn-ex99_1.htm)) |
| March 10, 2025 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/ex99-1.htm)) |
| March 10, 2025 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | PTGX | moderately to severely active ulcerative colitis3 | completed, positive | "Calif., March 10, 2025 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_ex99-2.htm)) |
| March 11, 2025 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/qttb-ex99_1.htm)) |
| March 11, 2025 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q4 AND FY 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-ex99_1.htm)) |
| March 11, 2025 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "CELEBRATION, Fla., Mar. 11, 2025 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended Dec. 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/ex_725374.htm)) |
| March 11, 2025 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312525051441/d890896dex991.htm)) |
| March 11, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Twelve" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125008092/ef20045222_ex99-1.htm)) |
| March 11, 2025 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/a12312024ex991.htm)) |
| March 11, 2025 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - March 11, 2025 - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828025012022/csbr8-k1312025ex991xq325.htm)) |
| March 11, 2025 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/lyel-20250311x8kexx991.htm)) |
| March 11, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025036829/agen-ex99_1.htm)) |
| March 11, 2025 | [VEPPANU (vepdegestrant) topline data readout](https://sec-api.dev/pdufa/vepdegestrant) | ARVN |  | completed, negative | "On March 11, 2025, Arvinas, Inc. (the "Company"), along with Pfizer, Inc. ("Pfizer"), announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive ("ER+"), human epidermal growth factor receptor 2-negative ("HER2-") ("ER+/HER2-") advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase ("CDK") 4/6 inhibitors and endocrine therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/arvn-20250311.htm)) |
| March 11, 2025 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-ex99_1.htm)) |
| March 11, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525051957/d937567dex991.htm)) |
| March 11, 2025 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/crbp-ex99_1.htm)) |
| March 11, 2025 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000155837025002708/mxct-20250311xex99d1.htm)) |
| March 12, 2025 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000095017025037618/amrn-ex99_1.htm)) |
| March 12, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Calif., March 12, 2025 - Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-1.htm)) |
| March 12, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025023220/ea023406001ex99-1_nektar.htm)) |
| March 12, 2025 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000095017025037619/upb-ex99_1.htm)) |
| March 12, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-ex99_1.htm)) |
| March 13, 2025 | [Cadrenal Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cvkd/catalysts) | CVKD |  | completed | "VEDRA, Fla., March 13, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/ea023436601ex99-1_cadrenal.htm)) |
| March 13, 2025 | [Cancer earnings report](https://sec-api.dev/pdufa/cancer) | ALLO |  | completed | "SOUTH SAN FRANCISCO, Calif., March 13, 2025 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000035/allo-20250313xexx9912024pr.htm)) |
| March 13, 2025 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "Holdings Reports Second Quarter Fiscal 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/ea023418101ex99-1_rafael.htm)) |
| March 13, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313xexx991.htm)) |
| March 13, 2025 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "ANN ARBOR, MI / ACCESSWIRE / March 13, 2025 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the fourth quarter and year-ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/zom_ex991.htm)) |
| March 13, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "CAMBRIDGE, Mass.March 13, 2025  Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2024 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751dex991.htm)) |
| March 13, 2025 | [Vafseo® (vadadustat) earnings report](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed | "Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/drafpr12312024.htm)) |
| March 13, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| March 13, 2025 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/ex99-1.htm)) |
| March 13, 2025 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/exhibit991_earningsrelease.htm)) |
| March 13, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025038757/cadl-ex99_1.htm)) |
| March 13, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/stro-ex99_1.htm)) |
| March 13, 2025 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/inab-ex99_1.htm)) |
| March 13, 2025 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/ints20250313ex99120241231p.htm)) |
| March 13, 2025 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/elvn-ex99_1.htm)) |
| March 13, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Financial Results for Year Ended 2024 and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925023216/tm259072d1_ex99-1.htm)) |
| March 13, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313xex991pressre.htm)) |
| March 13, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000095017025038711/rgnx-ex99_1.htm)) |
| March 13, 2025 | [ARBLI (losartan) FDA approval](https://sec-api.dev/pdufa/losartan) | SCNX |  | completed, approved | "NDA218772 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250313, review_priority STANDARD; sponsor_name SCIENTURE; product ARBLI (LOSARTAN POTASSIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218772%22)) |
| March 14, 2025 | [Fluocinolone label expansion decision](https://sec-api.dev/pdufa/fluocinolone) | ANIP | chronic non-infectious uveitis affecting the posterior segment of the eye | completed, approved | "On March 14, 2025, ANI Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has approved an expanded label for ILUVIEN® (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/ani-20250314.htm)) |
| March 14, 2025 | [Gvoke Kit (glucagon) label expansion decision](https://sec-api.dev/pdufa/glucagon) | XERS |  | completed, approved | "NDA212097 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250314, review_priority STANDARD; sponsor_name XERIS; product GVOKE KIT (GLUCAGON)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212097%22)) |
| March 17, 2025 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000095017025039837/mbx-ex99_1.htm)) |
| March 17, 2025 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On March 17, 2025, Travere Therapeutics, Inc. (the "Company") announced that it has submitted a supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/tvtx-20250317.htm)) |
| March 17, 2025 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, March 17, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/exhibit-991031725.htm)) |
| March 17, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317xex99d1.htm)) |
| March 17, 2025 | [NRX Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | completed | "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/ex_792256.htm)) |
| March 17, 2025 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm)) |
| March 17, 2025 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/sana-ex99_1.htm)) |
| March 17, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm)) |
| March 17, 2025 | [Opdivo® (nivolumab) trial start](https://sec-api.dev/pdufa/nivolumab) | CATX |  | completed | "On March 17, 2025, we announced that the first patient was dosed in the combination cohort, and on April 11, 2025, we announced that the first patient was dosed in the monotherapy cohort." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/728387/000095017025069314/catx-20250331.htm)) |
| March 17, 2025 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/exhibit991-q42024.htm)) |
| March 17, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/exhibit991-earningsrelease.htm)) |
| March 17, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/ex_791644.htm)) |
| March 17, 2025 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Reports Business Updates and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/mgx-ex99_1.htm)) |
| March 17, 2025 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/ex_790742.htm)) |
| March 17, 2025 | [Melanoma trial start](https://sec-api.dev/pdufa/melanoma) | CATX | histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans | completed | "SEATTLE - March 17, 2025 - Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/catx-ex99_1.htm)) |
| March 17, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000020/exhibit99112312024.htm)) |
| March 17, 2025 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Tenn., March 17, 2025 - Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315225010589/ex99-1.htm)) |
| March 17, 2025 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000095017025040417/prok-ex99_1.htm)) |
| March 17, 2025 | [Scienture Holdings, Inc. PDUFA date](https://sec-api.dev/companies/scnx/catalysts) | SCNX |  | scheduled | "In October 2024, the FDA accepted the resubmitted NDA for review and assigned a PDUFA target action date of March 17, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1382574/000149315226013475/form10-k.htm)) |
| March 17, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-ex99_1.htm)) |
| March 18, 2025 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/exhibit_99-1.htm)) |
| March 18, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/ino-123124x8kex991.htm)) |
| March 18, 2025 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625325000022/a2024q4ex991.htm)) |
| March 18, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Changes in estimates are reflected in reported results for the period in which they become known." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm)) |
| March 18, 2025 | [Biosimilar NDA/BLA acceptance](https://sec-api.dev/pdufa/biosimilar) | ALVO | osteoporosis in women | completed | "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03, a proposed biosimilar to Prolia and Xgeva (denosumab)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm)) |
| March 18, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, March 18, 2025 - Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm)) |
| March 18, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, March 18, 2025 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025041186/olma-ex99_1.htm)) |
| March 18, 2025 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/trvi-ex99_1.htm)) |
| March 18, 2025 | [CMND-100 trial start](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed | "Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today that it initiated its Phase I/IIa clinical trial investigating the safety, tolerability and full pharmacokinetic profile of its innovative treatment, CMND-100, in Alcohol Use Disorder (AUD) patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000101376225000571/ea023459001ex99-1_clearmind.htm)) |
| March 18, 2025 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/exh_991.htm)) |
| March 18, 2025 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/stok-ex99_1.htm)) |
| March 18, 2025 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125002787/ex99-1.htm)) |
| March 18, 2025 | [WEZLANA® (ustekinumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/ustekinumab) | ALVO |  | completed | "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm)) |
| March 18, 2025 | [EXICURE, INC. earnings report](https://sec-api.dev/companies/xcur/catalysts) | XCUR |  | completed | "Exicure, Inc. Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1698530/000169853025000017/a8kye2024exhibit991.htm)) |
| March 18, 2025 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/coya-ex99_1.htm)) |
| March 18, 2025 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/pyxs-ex99_1.htm)) |
| March 18, 2025 | [Acurx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/acxp/catalysts) | ACXP |  | completed | "Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736243/000110465925024731/tm259528d1_ex99-1.htm)) |
| March 18, 2025 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-ex99_1.htm)) |
| March 18, 2025 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Tivic Reports Year End 2024 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-ex99_1.htm)) |
| March 18, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/d839636dex991.htm)) |
| March 18, 2025 | [Prolia® (denosumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/denosumab) | ALVO | osteoporosis in women | completed | "On 18 March 2025 , the Company announced the FDA acceptance of BLA for AVT 03 , a proposed biosimilar to Prolia and Xgeva (denosumab) ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm)) |
| March 18, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925008137/ex_786379.htm)) |
| March 18, 2025 | [TAK-771 topline data readout](https://sec-api.dev/pdufa/tak-771) | TAK |  | completed | "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05084053?tab=results)) |
| March 19, 2025 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Inc. Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316825001693/xenetic_ex9901.htm)) |
| March 19, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)) |
| March 19, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_ex99-1.htm)) |
| March 19, 2025 | [Deramiocel NDA/BLA acceptance](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed | "Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm)) |
| March 19, 2025 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen Reports Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/dp226512_ex9901.htm)) |
| March 19, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025003304/capr-20250319xex99d1.htm)) |
| March 19, 2025 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the full year 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/tm259654d1_ex99-1.htm)) |
| March 19, 2025 | [CNTY-101 trial start](https://sec-api.dev/pdufa/cnty-101) | IPSC | B-cell mediated autoimmune diseases | completed | "2025, the company announced it had entered into an agreement for an investigator-initiated (IIT) Phase 1/2 trial by Professors Georg Schett and Andreas Mackensen of its CD19 CAR-iNK investigational cell therapy candidate CNTY-101 in patients with B-cell mediated autoimmune diseases." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/tm259654d1_ex99-1.htm)) |
| March 19, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm)) |
| March 19, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/tm259683d1_ex99-1.htm)) |
| March 19, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-170 (Efficacy): submission_status AP, submission_status_date 20250319, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| March 20, 2025 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/vtvt-20241231xexx991pressr.htm)) |
| March 20, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm)) |
| March 20, 2025 | [AMVUTTRA® (vutrisiran) FDA approval](https://sec-api.dev/pdufa/vutrisiran) | ALNY | ATTR Amyloidosis with Cardiomyopathy | completed, approved | "Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm)) |
| March 20, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025042317/spry-ex99_1.htm)) |
| March 20, 2025 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "NY - March 20, 2025 - Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/tm259712d1_ex99-1.htm)) |
| March 20, 2025 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000119312525058306/d679677dex991.htm)) |
| March 20, 2025 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000095017025042660/asmb-ex99_1.htm)) |
| March 20, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "CAMBRIDGE, Mass., March 20, 2025 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320xex99d1.htm)) |
| March 20, 2025 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/eras-ex99_1.htm)) |
| March 20, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "2 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014459/valnevapr24-3x25.htm)) |
| March 20, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "ROCKVILLE, MD., Mar 20, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000043/exhibit99-1earningspressre.htm)) |
| March 20, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/ivvd-ex99_1.htm)) |
| March 20, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/a250320_skyexye24financial.htm)) |
| March 20, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025042319/glue-ex99_1.htm)) |
| March 20, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/ex99-1.htm)) |
| March 20, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-ex99_1.htm)) |
| March 20, 2025 | [Autolus Therapeutics plc earnings report](https://sec-api.dev/companies/autl/catalysts) | AUTL |  | completed | "Exhibit 99.1 1 Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autlex-991pr200325.htm)) |
| March 20, 2025 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/tecx-ex99_1.htm)) |
| March 20, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/ex_792722.htm)) |
| March 20, 2025 | [AMVUTTRA® (vutrisiran) label expansion decision](https://sec-api.dev/pdufa/vutrisiran) | ALNY | cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis | completed, approved | "CAMBRIDGE, Mass. -- Mar. 20, 2025—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm)) |
| March 20, 2025 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000095017025042747/bioa-ex99_1.htm)) |
| March 20, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/imrx-20240229xexx9911.htm)) |
| March 20, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "LOS ANGELES, CA, March 20, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year ended December 31, 2024, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/armp-20250320xex99d1.htm)) |
| March 20, 2025 | [Joenja® (leniolisib) trial start](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000014/pharminggroupannouncesfirs.htm)) |
| March 20, 2025 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Reports 2024 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/ex-991fy2024earningsrelease.htm)) |
| March 20, 2025 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/a202503208kex991.htm)) |
| March 20, 2025 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Michigan, March 20, 2025 - Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months and twelve months ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000110465925025782/tm259810d1_ex99-1.htm)) |
| March 20, 2025 | [TLX007 FDA approval](https://sec-api.dev/pdufa/tlx007) | TLX |  | completed, approved | "Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000037/gozpr.htm)) |
| March 20, 2025 | [Gozellix (gallium ga-68 gozetotide) FDA approval](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide) | TLX |  | completed, approved | "NDA219592 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250320, review_priority STANDARD; sponsor_name TELIX INNOVATIONS; product GOZELLIX (GALLIUM GA-68 GOZETOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219592%22)) |
| March 20, 2025 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| March 20, 2025 | [FABHALTA® (iptacopan) label expansion decision](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "NDA218276 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22)) |
| March 21, 2025 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000149315225011082/ex99-1.htm)) |
| March 21, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/ex99-1.htm)) |
| March 21, 2025 | [Prezcobix (cobicistat; darunavir ethanolate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA205395 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20250321, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205395%22)) |
| March 21, 2025 | [Gozellix (gozellix) FDA approval](https://sec-api.dev/pdufa/gozellix) | TLX |  | completed, approved | "On 21 March 2025, the FDA approved the New Drug Application (NDA) for Gozellix®11, Telix's next-generation PSMA-PET imaging agent for prostate cancer that provides a longer shelf life of up to six hours and an extended distribution radius compared to existing gallium-based imaging products." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| March 23, 2025 | [AMVUTTRA® (vutrisiran) PDUFA date](https://sec-api.dev/pdufa/vutrisiran) | ALNY | with ATTR amyloidosis with cardiomyopathy | completed, approved | "** Guidance assumes FDA approval of the sNDA for vutrisiran for the treatment of adults with ATTR amyloidosis with cardiomyopathy by the March 23, 2025 PDUFA target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny2025q1exhibit991.htm)) |
| March 23, 2025 | [ALNYLAM PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | scheduled | "▪The FDA has accepted the sNDA and set an action goal date of March 23, 2025, under PDUFA" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| March 24, 2025 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/aura-ex99_1.htm)) |
| March 24, 2025 | [TLX007 PDUFA date](https://sec-api.dev/pdufa/tlx007) | TLX |  | completed, approved | "In July 2024, the FDA accepted the NDA for TLX007-CDx and assigned a PDUFA goal date of March 24, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm)) |
| March 24, 2025 | [Opthea Ltd topline data readout](https://sec-api.dev/companies/ckdxf/catalysts) | CKDXF |  | completed, negative | "Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in consultation with its Development Funding Agreement investors ("DFA Investors")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815620/000095017025047169/opt-ex99_1.htm)) |
| March 24, 2025 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774925008832/ex_793112.htm)) |
| March 24, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "DIEGO, CA, March 24, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/ex99-1.htm)) |
| March 24, 2025 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/ser-20250324xex991_earning.htm)) |
| March 24, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/artv-ex99_1.htm)) |
| March 24, 2025 | [Nomlabofusp earnings report](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed | "Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-ex99_1.htm)) |
| March 24, 2025 | [Interleukin trial start](https://sec-api.dev/pdufa/interleukin) | CANF |  | completed | "BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it initiated a pivotal phase 3 psoriasis study of its oral drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000101376225001262/ea023536201ex99-1_canfite.htm)) |
| March 24, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/lxeo-ex99_1.htm)) |
| March 24, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Fourth Quarter 2024 and Full Year Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000021/aeon-20250324xex99.htm)) |
| March 24, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/bolt-ex99_1.htm)) |
| March 24, 2025 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/ngne_4qyerelease.htm)) |
| March 24, 2025 | [Tivoxavir marboxil topline data readout](https://sec-api.dev/pdufa/tivoxavir-marboxil) | TRAW |  | completed, positive | "Marboxil, Shows Positive Data in Non-human Primates - (March 24, 2025) Traws Pharma, Inc. today announced positive topline results from a study evaluating the use of tivoxavir marboxil (TXM) as a treatment for non-human primates challenged with a non-lethal dose of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/tm2510891d1_ex99-1.htm)) |
| March 24, 2025 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "Reports Fiscal Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/exhibit991-q424.htm)) |
| March 24, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008869/ex_727055.htm)) |
| March 25, 2025 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Encinitas, California - March 25, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/ex991-pressreleasedecember.htm)) |
| March 25, 2025 | [X4 Pharmaceuticals, Inc earnings report](https://sec-api.dev/companies/xfor/catalysts) | XFOR |  | completed | "BOSTON, Mass., March 25, 2025 - X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted key 2024 and recent events and expected upcoming milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/a991earningsreleasedatedma.htm)) |
| March 25, 2025 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000155837025003587/apre-20250325xex99d1.htm)) |
| March 25, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "INC. REPORTS fourth QUARTER and full year 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520ex99-1_cormedix.htm)) |
| March 25, 2025 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "WELLESLEY HILLS, MASS., (GLOBE NEWSWIRE)  March 25, 2025  Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the quarter and year ended December 31, 2024, provided a business update, and reiterated anticipated program milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/d943630dex991.htm)) |
| March 25, 2025 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/tm2510115d1_ex99-1.htm)) |
| March 25, 2025 | [Gemzar (gemcitabine) interim data readout](https://sec-api.dev/pdufa/gemcitabine) | ACRV |  | completed, negative | "On March 25, 2025, the Company presented an interim data extract from the Electronic Data Capture (EDC) clinical database that was done on February 25, 2025, including 20 Oncosignature-positive, or BM+, endometrial cancer patients treated with ACR-368 monotherapy and 38 Oncosignature-negative, or BM-, patients treated with ACR-368 plus ultra low dose gemcitabine (LDG) that were efficacy-evaluable by RECIST (2 BM- had treatment discontinued without scan)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1781174/000095017025044549/acrv-20250325.htm)) |
| March 25, 2025 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/antx-ex99_1.htm)) |
| March 25, 2025 | [Berubicin topline data readout](https://sec-api.dev/pdufa/berubicin) | CNSP |  | completed, mixed | "On March 25, 2025, we released topline data that showed that although Berubicin produced clinically relevant outcomes that appear to be comparable (although the trial was not powered to determine non-inferiority) to Lomustine across multiple endpoints, it did not demonstrate a statistically significant difference in overall survival, the primary endpoint." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1729427/000168316825008466/cns_i10q-093025.htm)) |
| March 25, 2025 | [Simufilam topline data readout](https://sec-api.dev/pdufa/simufilam) | FLNA | mild-to-moderate Alzheimer's disease | completed, missed | "On March 25, 2025, the Company announced that the topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm)) |
| March 25, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/exh_991.htm)) |
| March 25, 2025 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000095017025044098/atos-ex99_1.htm)) |
| March 25, 2025 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000095017025044375/tennx-ex99_1.htm)) |
| March 25, 2025 | [Blujepa (gepotidacin mesylate) FDA approval](https://sec-api.dev/pdufa/gepotidacin) | GSK | To treat uncomplicated urinary tract infections | completed, approved | "Blujepa \| gepotidacin \| 3/25/2025 \| To treat uncomplicated urinary tract infectionsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| March 26, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925028226/tm2510555d1_ex99-1.htm)) |
| March 26, 2025 | [IGC Pharma, Inc. interim data readout](https://sec-api.dev/companies/igc/catalysts) | IGC |  | completed, positive | "March 26, 2025, the Company announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to AD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1326205/000118518525000706/igc10k033125.htm)) |
| March 26, 2025 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE, WASHINGTON - March 26, 2025 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/catx-ex99_1.htm)) |
| March 26, 2025 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000164117225000689/ex99-1.htm)) |
| March 26, 2025 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000095017025044783/mreo-ex99_1.htm)) |
| March 26, 2025 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/nktx-ex99_1.htm)) |
| March 26, 2025 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516025000070/zntl_q42024earningspr.htm)) |
| March 26, 2025 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "DYADIC REPORTS 2024 YEAR-END FINANCIAL RESULTS AND BUSINESS UPDATES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000143774925009351/ex_727220.htm)) |
| March 26, 2025 | [Cabometyx (cabozantinib s-malate) label expansion decision](https://sec-api.dev/pdufa/cabozantinib-s-malate) | EXEL |  | completed, approved | "NDA208692 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20250326, review_priority STANDARD; sponsor_name EXELIXIS INC; product CABOMETYX (CABOZANTINIB S-MALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208692%22)) |
| March 26, 2025 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/dtil-ex99_1.htm)) |
| March 26, 2025 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "MA - March 26, 2025 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465925028015/tm2510101d2_ex99-1.htm)) |
| March 26, 2025 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports 2024 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/ex_794787.htm)) |
| March 27, 2025 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184325001760/exh_991.htm)) |
| March 27, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/d906623dex991.htm)) |
| March 27, 2025 | [XYNGARI (DMT310) topline data readout](https://sec-api.dev/pdufa/dmt310) | DRMA |  | completed, positive | "SAN DIEGO, CA, March 27, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_ex991.htm)) |
| March 27, 2025 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "-- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a clinical-stage biotechnology company, today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/ea023600601ex99-1_relmada.htm)) |
| March 27, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327xexx991.htm)) |
| March 27, 2025 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/exh_991.htm)) |
| March 27, 2025 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000202365825000006/pressreleaseq42024.htm)) |
| March 27, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/adct-20241231pressrelease.htm)) |
| March 27, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000009/sttk_ye2024earningsrelease.htm)) |
| March 27, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports 2024 Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/ex_795727.htm)) |
| March 27, 2025 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug development enhancements, and other operational progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000164117225000917/ex99-1.htm)) |
| March 27, 2025 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces Fourth-Quarter and Year-End 2024 Audited Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000164117225000915/ex99-1.htm)) |
| March 27, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025003807/ganx-20250327xex99d1.htm)) |
| March 27, 2025 | [BioAtla, Inc. earnings report](https://sec-api.dev/companies/bcab/catalysts) | BCAB |  | completed | "BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/bcab-ex99_1.htm)) |
| March 27, 2025 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Year End 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/tpst-ex99_1.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm)) |
| March 27, 2025 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000095017025046067/kod-ex99_1.htm)) |
| March 27, 2025 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | " March 27, 2025  Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312525064729/d906388dex991.htm)) |
| March 27, 2025 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MARCH 27, 2025, ENTITLED THERAPEUTICSMD ANNOUNCES FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/ea023520001ex99-1_therap.htm)) |
| March 27, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/eq-ex99_1.htm)) |
| March 27, 2025 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036125010575/ef20046266_ex99-1.htm)) |
| March 27, 2025 | [Inmune Bio, Inc. earnings report](https://sec-api.dev/companies/inmb/catalysts) | INMB |  | completed | "Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711754/000101376225003401/ea023558402ex99-1_inmune.htm)) |
| March 27, 2025 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000095017025046052/kytx-ex99_1.htm)) |
| March 27, 2025 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/a20250327form8-kxexhibit991.htm)) |
| March 27, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_ex99-1.htm)) |
| March 27, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525065511/d943685dex991.htm)) |
| March 27, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/tyra-ex99_1.htm)) |
| March 27, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/ck0001534133-ex99_1.htm)) |
| March 27, 2025 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/bold-ex99_1.htm)) |
| March 27, 2025 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/cvsi-ex99_1.htm)) |
| March 27, 2025 | [CARDAMYST (etripamil) complete response letter (CRL)](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218571_20250327.pdf%22)) |
| March 27, 2025 | [Rivfloza (nedosiran sodium) label expansion decision](https://sec-api.dev/pdufa/nedosiran) | NVO |  | completed, approved | "NDA215842 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250327, review_priority STANDARD; sponsor_name NOVO; product RIVFLOZA (NEDOSIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215842%22)) |
| March 28, 2025 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325001110/exhibit_99-1.htm)) |
| March 28, 2025 | [YUTREPIA (treprostinil) NDA/BLA acceptance](https://sec-api.dev/pdufa/treprostinil) | LQDA | rare cardiopulmonary disease, today | completed | "As previously disclosed on March 28, 2025, the FDA has accepted the Company's NDA resubmission for YUTREPIA to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease and has set a Prescription Drug User Fee Act ("PDUFA") goal date of May 24, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_8k.htm)) |
| March 28, 2025 | [PL8177 topline data readout](https://sec-api.dev/pdufa/pl8177) | PTN |  | completed, positive | "CRANBURY, NJ - March 28, 2025/PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis (UC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/ptn_ex991.htm)) |
| March 28, 2025 | [CTEXLI® (chenodiol) PDUFA date](https://sec-api.dev/pdufa/chenodiol) | MIRM |  | completed, approved | "•FDA Prescription Drug User Fee Act (PDUFA) date for chenodiol in cerebrotendinous xanthomatosis (CTX) is March 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113xexx991.htm)) |
| March 28, 2025 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL - March 28, 2025 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000095017025046716/hcwb-ex99_1.htm)) |
| March 28, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/huma-20250328xexx991.htm)) |
| March 28, 2025 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGVHD in December 2024, as well | completed, approved | "Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000058/exhibit991.htm)) |
| March 28, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-ex99_1.htm)) |
| March 28, 2025 | [Imfinzi® (durvalumab) label expansion decision](https://sec-api.dev/pdufa/durvalumab) | AZN |  | completed, approved | "BLA761069 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22)) |
| March 28, 2025 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/d927069dex991.htm)) |
| March 28, 2025 | [Qfitlia™ (fitusiran) FDA approval](https://sec-api.dev/pdufa/fitusiran) | SNY | To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress Release | completed, approved | "Qfitlia \| fitusiran \| 3/28/2025 \| To prevent or reduce the frequency of bleeding episodes in hemophilia A or BPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| March 28, 2025 | [Pluvicto (lutetium lu-177 vipivotide tetraxetan) label expansion decision](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan) | NVS |  | completed, approved | "NDA215833 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22)) |
| March 29, 2025 | [Lorundrostat topline data readout](https://sec-api.dev/pdufa/lorundrostat) | MLYS |  | completed, positive | "Following the recently announced positive topline data from both Advance-HTN and Launch-HTN pivotal trials, detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys202503318kex991.htm)) |
| March 31, 2025 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "SAN FRANCISCO, CA / March 31, 2025 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/jagx-ex99_1.htm)) |
| March 31, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/rani-ex99_1.htm)) |
| March 31, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331xex99d1.htm)) |
| March 31, 2025 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., March 31, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000028/a4q24earningspressrelease.htm)) |
| March 31, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/ex_749944.htm)) |
| March 31, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| March 31, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Full Year 2024 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/ex99-1.htm)) |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "We submitted a New Drug Application ("NDA") for the treatment of children with achondroplasia on March 31, 2025 and the FDA has accepted for priority review our NDA for TransCon CNP (navepegritide)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm)) |
| March 31, 2025 | [VAX-24 topline data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed, positive | "SAN CARLOS, Calif., March 31, 2025  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today shared positive topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the Companys 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® (PCV20) in healthy infants." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm)) |
| March 31, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA submission](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | completed | "On March 31, 2025, we submitted to the FDA a new drug application, or NDA, for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| March 31, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "WILMETTE, Ill., March 31, 2025 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/ex_795025.htm)) |
| March 31, 2025 | [Varegacestat trial start](https://sec-api.dev/pdufa/varegacestat) | IMNM |  | completed | "(2) The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to increased clinical trial activities as we initiated our Phase 1 trial in February 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000155837025007382/tmb-20250331x10q.htm)) |
| March 31, 2025 | [Marker Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mrkr/catalysts) | MRKR |  | completed | "Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/tm2510813d1_ex99-1.htm)) |
| March 31, 2025 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/bmea-ex99_1.htm)) |
| March 31, 2025 | [ProPhase Labs, Inc. earnings report](https://sec-api.dev/companies/prph/catalysts) | PRPH |  | completed | "Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/ex99-1.htm)) |
| March 31, 2025 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000095017025047196/caba-ex99_1.htm)) |
| March 31, 2025 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/ex_796728.htm)) |
| March 31, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/ef20046473_ex99-1.htm)) |
| March 31, 2025 | [OS Therapies Inc earnings report](https://sec-api.dev/companies/ostx/catalysts) | OSTX |  | completed | "Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended December 31, 2024 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1795091/000121390025026322/ea023643601ex99-1_ostherapi.htm)) |
| March 31, 2025 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000095017025047769/ck0001774857-ex99_1.htm)) |
| March 31, 2025 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/cntbpressreleaseyear-endre.htm)) |
| March 31, 2025 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the year ended December 31, 2024 and provided recent business highlights, with updates to the Company's investigational programs including lead product candidate, tivoxavir marboxil (TXM) in development for bird flu, and ratutrelvir in development for COVID." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/tm2510891d1_ex99-1.htm)) |
| March 31, 2025 | [Vafseo® (vadadustat) FDA approval](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed, approved | "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm)) |
| March 31, 2025 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000164117225001822/ex99-1.htm)) |
| March 31, 2025 | [Selcodebart trial start](https://sec-api.dev/pdufa/selcodebart) | IRON |  | completed | "During the three months ended March 31, 2025, the Company dosed the first patient in the Phase 2 clinical trial of DISC-0974." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm)) |
| March 31, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025047207/maze-ex99_1.htm)) |
| March 31, 2025 | [Imeroprubart trial start](https://sec-api.dev/pdufa/imeroprubart) | IMVT | active, anti-citrullinated protein autoantibody | completed | "For example, we expect our research and development expenses to significantly increase as we seek to execute our plan to initiate four to five potentially registrational programs for IMVT-1402 by March 31, 2025 and initiate trials of IMVT-1402 in ten indications (inclusive of the four to five programs initiated in fiscal 2025) by March 31, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm)) |
| March 31, 2025 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/ex99-1.htm)) |
| March 31, 2025 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "ANTONIO, Texas (March 31, 2025) - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000164117225001519/ex99-1.htm)) |
| March 31, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "The decrease in research and development expenses for the three months ended March 31, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674425000010/gern-20250331.htm)) |
| March 31, 2025 | [Stenoparib trial start](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "Combination Trial Launched: Allarity announced a new Phase 2 trial evaluating stenoparib in combination with temozolomide for recurrent small cell lung cancer (SCLC), fully funded by the U.S. Veterans Administration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/ex_796943.htm)) |
| March 31, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331xex99d1.htm)) |
| March 31, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125011174/ef20046120_ex99-1.htm)) |
| March 31, 2025 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "ATLANTA, Ga., March 31, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/dwtx-20250331xex99d1.htm)) |
| March 31, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of March 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated the investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000095017025069125/cue-20250331.htm)) |
| March 31, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/cue-ex99_1.htm)) |
| March 31, 2025 | [Zymeworks Inc. trial start](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Revenue for the three months ended March 31, 2025 included $14.0 million of milestone revenue from GSK in relation to a clinical milestone under our 2016 platform technology transfer and license agreement, $3.1 million of milestone revenue from Daiichi Sankyo following the first patient dosed in a clinical trial related to our 2018 license agreement, $9.6 million for development support and drug supply revenue in addition to $0.2 million of royalty income from Jazz and $0.2 million of drug supply revenue from BeiGene." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000026/ex991q12025_earningsxrelea.htm)) |
| March 31, 2025 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT |  | completed, met | "Immunovant intends to report top-line results from the pivotal trial of batoclimab in MG by March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm)) |
| March 31, 2025 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio today reported its financial results for the year ended December 31, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000168316825002131/phio_ex9901.htm)) |
| March 31, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/tm2510890d2_ex99-1.htm)) |
| March 31, 2025 | [Tonix Pharmaceuticals Holding Corp. NDA/BLA acceptance](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "During the three months ended March 31, 2025, warrants totaling 10,884 became exercisable, 5,758 became exercisable upon FDA acceptance of our NDA filing, and 1, with an exercise price of $1,056," ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937126010486/tnxp-10q_033126.htm)) |
| March 31, 2025 | [Allarity Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allr/catalysts) | ALLR |  | completed | "Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/ex_796943.htm)) |
| March 31, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/ex99-1.htm)) |
| March 31, 2025 | [UNI-494 NDA/BLA acceptance](https://sec-api.dev/pdufa/uni-494) | UNCY | hyperphosphatemia in patients with CKD | completed | "Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm)) |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA submission](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "On March 31, 2025, the Company announced that it has submitted its New Drug Application to the U.S. Food & Drug Administration for TransCon CNP (navepegritide) for the treatment of children with achondroplasia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525068722/d923652d6k.htm)) |
| March 31, 2025 | [BRIUMVI® (ublituximab) FDA approval](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed, approved | "At March 31, 2025, all our inventory was solely related to BRIUMVI, which was approved by the FDA on December 28, 2022, at which time we began to capitalize costs to manufacture BRIUMVI." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1001316/000143774925015804/tgtx20250331_10q.htm)) |
| March 31, 2025 | [AUCATZYL (obecabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed, approved | "During the three months ended March 31, 2025, we generated product revenue, net in the amount of $9.0 million, from the sale of AUCATZYL in the United States, We did not generate any product revenue, in the three months ended March 31, 2024, as AUCATZYL was approved by the FDA for commercial use on November 8, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000039/autl-20250331.htm)) |
| March 31, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/ex_796258.htm)) |
| March 31, 2025 | [Zopapogene imadenovec FDA approval](https://sec-api.dev/pdufa/zopapogene-imadenovec) | PGEN |  | completed, approved | "R&D expenses decreased by $4.8 million compared to the three months ended March 31, 2025, primarily due to the change in the accounting treatment of manufacturing costs as a result of the FDA approval of PAPZIMEOS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_ex9901.htm)) |
| March 31, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-ex99_1.htm)) |
| March 31, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331xex99d1.htm)) |
| March 31, 2025 | [Nomlabofusp trial start](https://sec-api.dev/pdufa/nomlabofusp) | LRMR |  | completed | "The increase was primarily driven by an increase of $7.1 million in nomlabofusp manufacturing costs, an increase of $2.8 million in clinical costs primarily associated with the ongoing pediatric study which started and completed patient enrollment in the quarter ended March 31, 2025 and the start of our planned global Phase 3 study in the first quarter of 2025, an increase of $1.6 million in personnel expense due to increased headcount, and an increase of $1.2 million in consulting fees." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374690/000095017025061222/lrmr-20250331.htm)) |
| March 31, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB |  | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the three months ended March 31, 2025, and paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm)) |
| March 31, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "[2] Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025015897/valnevapr4-1x2025.htm)) |
| March 31, 2025 | [Protocol FDA approval](https://sec-api.dev/pdufa/protocol) | AIM |  | completed, approved | "For the three months ended March 31, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000164117225011033/form10-q.htm)) |

Other months: https://sec-api.dev/fda-calendar/2025-02 , https://sec-api.dev/fda-calendar/2025-04. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates March 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-03

```bibtex
@misc{secapidev_fda_calendar_2025_03_20261116,
  title        = {PDUFA dates March 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-03}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_03_20261116","title":"PDUFA dates March 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-03","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
